prostate Articles
-
Low-dose irradiation for controlling prostate cancer
Prostate cancer is the second most commonly diagnosed cancer among North American men and the second leading cause of death in those aged 65 and over. The US Cancer Society recommends testing those over 50 years of age who are expected to live at least for 10 years, even though the ability of early detection to decrease prostate cancer mortality has not been demonstrated. A controversy exists ...
-
Validation of ClarityDX Prostate as a Reflex Test to Refine Prediction of Clinically Significant Prostate Cancer: ClinicalTrials.gov ID: NCT03957252
Summary This study is designed to determine the accuracy of the blood test ClarityDX Prostate to predict the results of prostate biopsies in men who have PSA (Prostate Specific Antigen) greater than 3 and no higher than 10 ...
-
An independent assessment of AI for prostate cancer detection - Case Study
Yale Medicine, an academic medical center with a high volume of prostate biopsies, conducted a study to determine Paige Prostate’s utility as a prescreening tool for clinical use. A total of 1,876 prostate core biopsy slides were analyzed by Paige Prostate, and only those cores categorized by the AI as “suspicious” or as out of distribution were manually reviewed by Yale ...
-
Design and analysis of nanowire sensor array for prostate cancer detection
Prostate cancer is one of the major cancer affecting men in India. After lung cancer, prostate cancer has caused large number of deaths in India. Nanowire is the biosensor used for detection of cancer. In this paper, we present a design of nanowire array sensor for prostate cancer detection. A sensor array of 8 × 8 elements is designed to capture the PSA present in the blood that helps in ...
-
Allium TM TPS—A New Prostatic Stent for the Treatment of Patients with Benign Prostatic Obstruction: The First Report
Introduction: Several prostatic stents were developed in the last three decades, none of which were able to provide a real alternative in patients unfit or unwilling to undergo classical prostatic surgeries. In this study, we report the results of the use of a newly developed prostatic stent—the Allium™ Triangular Prostatic Stent (TPS). Patients and Methods: The Allium TPS is a ...
By Allium Ltd
-
High-resolution Map of Somatic Periprostatic Nerves
Objective To generate a high-resolution map of periprostatic somatic nerves. Periprostatic nerves are at risk of injury during radical prostatectomy; this study aimed to establish the location of somatic nerves with respect to the prostate and the neurovascular bundle. Materials and Methods Hemiprostates from patients in whom a wide local excision was performed were evaluated. Representative ...
-
Nanostics Announces Study Data Supporting ClarityDX Prostate as a Reflex Test to Predict Clinically Significant Prostate Cancer
Real-world data shows that at a 94% sensitivity level for prostate cancer ClarityDX Prostate® is 147% more specific than the PSA test for predicting clinically significant prostate cancer. Using ClarityDX Prostate® as a reflex test vs. PSA test alone could have resulted in 37% fewer unnecessary biopsies. The clinical study recruited men from two sites in Alberta, Canada, and one site ...
-
Nanostics Receives CE Mark for its ClarityDX Prostate Test to Detect Clinically Significant Prostate Cancer
Nanostics’ biomarker and machine learning-powered test, ClarityDX Prostate®, received a CE-IVD Mark. A CE-IVD Mark is required for all in vitro diagnostic (IVD) devices to be placed in the European Economic Area, Iceland, Norway, and Liechtenstein and allows Nanostics to market and sell ClarityDX Prostate® in these countries. The ClarityDX Prostate® test provides patients ...
-
Movember Together: How Paige, University of Oxford, and Prostate Cancer UK Are Working to Change the Prostate Cancer Experience
Movember is an annual initiative where men from around the globe grow mustaches to raise awareness for men’s health causes, including mental health and suicide prevention, testicular cancer, and prostate cancer. Through events, fundraising, and using mustaches as a light-hearted starting point for important conversations, the movement supports men in taking charge of their health to live ...
-
Bio-tech firm recruiting Yukon men for trial, Prostate cancer group says it could save lives
The Yukon chapter of Ride For Dad says a new blood test developed by an Alberta-based company could save the lives of men at risk of prostate cancer. (iStock/Getty Images) A bio-technology company based in Alberta is testing a new process that could result in fewer Yukon men travelling out of territory for prostate cancer biopsies. Private research company Nanostics Inc. and the University of ...
-
Partech Movember Challenge!
This November six members of the Partech team will be growing and grooming moustaches in aid of the ‘Movember Foundation’.The ‘Movember Foundation’ is a global charity committed to men living happier, healthier and longer lives. The charity was set up in 2003 and since then millions have joined the men’s health movement raising £443 million and funding over ...
-
Phase lb study of venadaparib, a potent and selective PARP inhibitor, in homologous recombination repair (HRR) mutated breast cancer
Poly ADP-ribose polymerase (PARP) is an enzyme that is central to the repair of DNA replication errors and are currently approved for ovary, breast, pancreas and prostate cancers. VASTUS study (NCT04174716)1' is a basket trial investigating the safety and efficacy of venadaparib in 6 cohorts (active recruiting) of different tumors, including breast ...
-
Evaluation of an Epigenetic Assay for Predicting Repeat Prostate Biopsy Outcome in African American Men
Abstract Objective: To evaluate an epigenetic assay performed on tissue from negative prostate biopsies in a group of African American (AA) men undergoing repeat biopsy, and to compare accuracy for predicting repeat biopsy outcome to prior studies conducted in predominantly Caucasian populations. Materials and methods: The study population consisted of 211 AA men from 7 urology centers ...
By MDxHealth
-
Risk score predicts high-grade prostate cancer in DNA-methylation positive, histopathologically negative biopsies
Abstract Background: Prostate cancer (PCa) diagnosis is challenging because efforts for effective, timely treatment of men with significant cancer typically result in over-diagnosis and repeat biopsies. The presence or absence of epigenetic aberrations, more specifically DNA-methylation of GSTP1, RASSF1, and APC in histopathologically negative prostate core biopsies has resulted in an ...
By MDxHealth
-
Cost-Effectiveness of Urinary Biomarker Panel in Prostate Cancer Risk Assessment
Abstract Purpose: SelectMDx (MDxHealth®) is a panel of urinary biomarkers used in conjunction with traditional risk factors to individualize risk prediction for clinically significant prostate cancer. In this study we sought to characterize the effectiveness of SelectMDx in a population of American men with elevated prostate specific antigen. Materials and methods: We developed a ...
By MDxHealth
-
Nanostics Re-Opens ClarityDX Prostate Clinical Study with New US Recruitment Site
Summary Nanostics' clinical validation study for ClarityDX Prostate, a liquid biopsy test for the early diagnosis of clinically significant prostate cancer, re-opens recruitment after lifting of COVID-19 research restrictions A top-ranked research institute in the Northeast US will now partner with Nanostics' by recruiting patients for the clinical validation study This partnership will ...
-
First-in-Human Dose Finding Study of Venadaparib (IDX-1197), a Potent and Selective PARP inhibitor, in Patients with Advanced Solid Tumors
Poly ADP-ribose polymerase (PARP) is an enzyme that is central to the repair of DNA replication errors known as single-strand breaks. PARP inhibitors are currently approved (or ovary, breast, pancreatic and prostate cancers which harbor BRCA1/2 mutations and/or homologous recombinant repair mutation. In this phase 1 dose escalation study of venadaparib, we determined the maximum tolerated dose ...
-
Validation of a two-gene mRNA urine test for detection of high-grade prostate cancer in German men.
Organizations Martini-Klinik Prostate Cancer Center and Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany, MDxHealth, B.V., Nijmegen, Netherlands, MDxHealth, Inc., Irvine, CA, Mathematical Modeling, Statistics and Bioinformatics, Ghent University, Ghent, Belgium, Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany Abstract ...
By MDxHealth
-
Antibody-Drug Conjugates For The Treatment of Prostate Cancer
Currently, ADC has played a significant role in the treatment of some malignant tumors, such as trastuzumab in the treatment of breast cancer, but its application in the treatment of prostate cancer (PCa) progress slowly. In recent years, ADC has made rapid progress in the treatment of metastatic castration-resistant prostate cancer (mCRPC). STEAP1, TROP2, PSMA, CD46, and B7-H3 are currently ...
-
Acibadem Hospitals Digital Pathology Project - Case study
Virasoft provides digital pathology systems that optimize the pathology workflow with digital slide management, slide viewing and quantitative image analysis for Acibadem Hospitals pathology laboratories. In partnership with Acibadem Hospitals and Virasoft, artificial intelligence projects are being developed for several cancer diagnosis. Digital Pathology System ViraCenter is an integrated ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you